Literature DB >> 9281346

Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells.

M Li1, B Choo, Z M Wong, J Filmus, R N Buick.   

Abstract

OCI-5, the rat homologue of human glypican 3 (GPC3), is believed to be involved in morphogenesis and growth control during development. The finding that GPC3 is mutated in patients with the Simpson-Golabi-Behmel overgrowth syndrome is consistent with this idea. In this report, using RNA in situ hybridization, expression of OCI-5 in the developing intestine is detected in both endoderm- and mesenchyme-derived cells in a phased manner related to age and proximal/distal position. To investigate the mechanism of its regulation during intestinal development, OCI-5 expression was studied in the primitive rat intestinal epithelial cell line IEC-18. The expression of the OCI-5 transcript is increased in IEC-18 cells at confluence, in low calcium media, and during spheroid culture, all conditions which result in the cells acquiring a more rounded cell shape. In contrast, cytoskeletal disruption with colchicine causes cells to flatten and spread and abolishes both the confluence- and the low calcium-dependent induction of OCI-5. Treatment with vanadate, a phosphatase inhibitor, causes cells to acquire a spindle-shaped morphology and prevents OCI-5 induction in all situations. Nuclear run-on analysis demonstrates that the rate of OCI-5 transcription is increased at confluence, in low calcium media, and during spheroid culture of IEC-18, and decreased by treatment of cells with colchicine. Together, these data suggest that OCI-5 expression is regulated in IEC-18 by cell shape. The pattern of expression of OCI-5 in the developing intestine is consistent with it playing a role in epithelial-mesenchymal interactions during intestinal morphogenesis, when cell shape changes are likely to occur.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281346     DOI: 10.1006/excr.1997.3629

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

Review 1.  Glypicans: proteoglycans with a surprise.

Authors:  J Filmus; S B Selleck
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 2.  The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans.

Authors:  Jorge Filmus
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

3.  Cloning and expression of MXR7 gene in human HCC tissue.

Authors:  Xue-Ping Zhou; Hong-Yang Wang; Guang-Shun Yang; Zheng-Jun Chen; Bao-An Li; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

4.  Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.

Authors:  Nan Li; Haiying Fu; Stephen M Hewitt; Dimiter S Dimitrov; Mitchell Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

Review 5.  Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.

Authors:  Yukihiro Haruyama; Hiroaki Kataoka
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

6.  Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.

Authors:  Regina Cheuk-Lam Lo; Irene Oi-Lin Ng
Journal:  Chin J Cancer Res       Date:  2011-12       Impact factor: 5.087

Review 7.  Systemic therapy of hepatocellular carcinoma: current status and future perspectives.

Authors:  Domenico Germano; Bruno Daniele
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

8.  Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.

Authors:  Masafumi Ikeda; Shinichi Ohkawa; Takuji Okusaka; Shuichi Mitsunaga; Satoshi Kobayashi; Chigusa Morizane; Ikue Suzuki; Shunsuke Yamamoto; Junji Furuse
Journal:  Cancer Sci       Date:  2014-03-25       Impact factor: 6.716

9.  Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Authors:  Ahmed Omar Kaseb; Manal Hassan; Sahin Lacin; Reham Abdel-Wahab; Hesham M Amin; Ahmed Shalaby; Robert A Wolff; James Yao; Asif Rashid; Bharathi Vennapusa; Janine Feng; Toshihiko Ohtomo
Journal:  Oncotarget       Date:  2016-10-25

10.  Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.

Authors:  Lilian Fedra Castillo; Rocío Tascón; María Amparo Lago Huvelle; Gisela Novack; María Candelaria Llorens; Ancely Ferreira Dos Santos; Jorge Shortrede; Ana María Cabanillas; Elisa Bal de Kier Joffé; Leticia Labriola; María Giselle Peters
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.